SecurityHRMNU / Harmony Merger Corp. (413247206)
Institutional Owners29
Institutional Shares113,722,722 - 106.88%
Institutional Value$ 145,180,000 USD

Institutional Stock Ownership and Shareholders

Harmony Merger Corp. (NASDAQ:HRMNU) has 29 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 113,722,722 shares. Largest shareholders include York Capital Management Global Advisors, LLC, Valinor Management, Llc, Halcyon Mount Bonnell Fund Lp, Halcyon Management Partners LP, Eisbrenner Kathleen, General Electric Co, Highland Capital Management Lp, Vanguard Group Inc, Davidson Kempner Partners, and TPH Asset Management, LLC.

Harmony Merger Corp. (NASDAQ:HRMNU) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.


File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-15 13F-HR JANE STREET GROUP, LLC 42,189 0 -100.00 426 0 -100.00
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 35,251 294
2018-02-12 SC 13G/A DAVIDSON KEMPNER PARTNERS 925,000 780,150 -15.66
2018-04-13 SC 13D/A York Capital Management Global Advisors, LLC 57,743,859
2018-04-18 13F-HR DEPRINCE RACE & ZOLLO INC 18,826 42,600 126.28 157 210 33.76
2017-11-14 13F-HR Bulldog Investors, LLC 195,386 0 -100.00 156 0 -100.00
2018-02-14 13F-HR GOLDMAN SACHS GROUP INC 91,725 12,418 -86.46 926 103 -88.88
2018-04-13 SC 13D/A VALINOR MANAGEMENT, LLC 19,457,313 19,506,984 0.26
2018-02-14 13F-HR BlueCrest Capital Management Ltd 45,151 55,497 22.91 456 462 1.32
2018-02-14 13F-HR VANGUARD GROUP INC 998,856 1,605,848 60.77 10,078 13,361 32.58
2018-02-12 13F-HR Spark Investment Management LLC 10,700 0 -100.00 107 0 -100.00
2018-03-05 13F-HR/A-1 BNP PARIBAS ARBITRAGE, SA 368 0 -100.00 3,713 0 -100.00
2018-04-18 13F-HR/A-1 FNY Managed Accounts LLC 500 0 -100.00 4 0 -100.00
2018-02-14 13F-HR MORGAN STANLEY 39,718 8,216 -79.31 401 68 -83.04
2017-11-14 13F-HR Rotation Capital Management, LP 381,596 0 -100.00 305 0 -100.00
2018-02-13 13F-HR PIONEER INVESTMENT MANAGEMENT INC 4,286 36
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 1,686 0 -100.00 17 0 -100.00
2017-11-09 13F-HR TD ASSET MANAGEMENT INC 818,200 0 -100.00 655 0 -100.00
2018-02-14 13F-HR Paloma Partners Management Co 12,900 107
2018-02-14 13F-HR Neuberger Berman Group LLC 13,178 110
2018-02-09 13F-HR Bank of New York Mellon Corp 10,470 87
2018-02-14 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 2,106,655 2,089,555 -0.81 21,256 17,385 -18.21
2017-11-14 13F-HR CNH PARTNERS LLC 1,375,100 0 -100.00 1,100 0 -100.00
2018-02-14 13F-HR DEUTSCHE BANK AG\ 8,072 67
2018-04-14 SC 13D/A Halcyon Mount Bonnell Fund Lp 9,511,903 9,535,910 0.25
2018-02-14 13F-HR UBS Group AG 1,341 0 -100.00 14 0 -100.00
2018-02-13 13F-HR GENERAL ELECTRIC CO 3,211,121 3,211,121 0.00 32,400 26,717 -17.54
2018-02-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 33,138 276
2018-02-12 13F-HR Atlantic Trust Group, LLC 4,900 41
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 256,691 54,153 -78.90 2,590 451 -82.59
2018-02-09 13F-HR Monashee Investment Management LLC 143
2017-11-09 13F-HR K2 PRINCIPAL FUND, L.P. 1,399,379 0 -100.00 14,458 0 -100.00
2018-02-13 13F-HR GEODE CAPITAL MANAGEMENT, LLC 106,055 179,897 69.63 1,070 1,496 39.81
2018-02-13 13F-HR TVR Capital Management LP 26,000 0 -100.00 263 0 -100.00
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 11,495 0 -100.00 116 0 -100.00
2018-01-17 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 33,461 36,425 8.86 338 304 -10.06
2018-03-20 SC 13D/A Eisbrenner Kathleen 8,685,633
2018-02-14 13F-HR Halcyon Management Partners LP 9,434,530 9,418,153 -0.17 95,194 78,359 -17.68
2018-02-14 13F-HR Polar Asset Management Partners Inc. 80,000 80,000 0.00 726 599 -17.49
2018-02-14 13F-HR ROYAL BANK OF CANADA 19 0 -100.00 0 0
2017-11-14 13F-HR WOLVERINE ASSET MANAGEMENT LLC 54,531 0 -100.00 43 0 -100.00
2018-02-14 13F-HR Covalent Partners LLC 274,649 182,231 -33.65 2,587 1,410 -45.50
2018-02-14 13F-HR TPH Asset Management, LLC 190,817 371,835 94.86 1,925 3,094 60.73
2017-11-14 13F-HR Davidson Kempner Capital Management LP 830,250 0 -100.00 664 0 -100.00
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 42 0

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 413247206